Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

61509 1497862462HCLSReviewTaiwanJune2017.pdf
Energy Boardroom

Merck snatches Idenix for $3.8B as it watches Sovaldi gobble up market share

09.06.2014 / Fierce Pharma

Sovaldi's runaway success looms large over Merck's decision to ante up $3.8 billion to buy Idenix Pharmaceuticals, which has three hepatitis C drugs in early stage development. Gilead's hep C drug has given an early peek at just how large the market is and how extensive it will be for years to come, an opportunity Merck hopes to exploit by acquiring more hep C firepower.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: